BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 35 th Annual Deutsche Bank Healthcare Conference to be held in the InterContinental Hotel, Boston from May 3-5, 2010. Phillip Donenberg, BioSante’s CFO, will speak on Monday May 3, 2010 at 2:10 EDT. He will provide an overview of the company, as well as an update on LibiGel ® (testosterone gel) in Phase III clinical development for the treatment of female sexual dysfunction and BioSante’s portfolio of cancer vaccines in Phase II clinical development. About the Deutsche Bank Healthcare Conference The 35 th Annual Deutsche Bank Healthcare Conference will be held May 3 - 5, 2010 at the InterContinental Hotel in Boston. The Conference will feature senior executives from over 150 of the health care industry's most prestigious public and private pharmaceutical and biotech companies providing presentations to update institutional investors, portfolio managers and analysts interested in these sectors. About BioSante Pharmaceuticals, Inc. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development is a portfolio of cancer vaccines (GVAX), two of which have been granted orphan drug designation, currently in several Phase II clinical trials, at minimal cost to BioSante. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.